OBJECTIVES: This study was conducted to assess the systemic drug release and distribution of sirolimus-eluting coronary stents. METHODS: Twenty patients with coronary artery disease (CAD) were treated with 1, 2, or 3 a newly designed metallic stents. Blood samples were drawn at 14 time points to determine the pharmacokinetic of sirolimus. Whole blood concentrations of sirolimus were determined by using a sensitive validated high-performance liquid chromatography mass spectrometry/mass spectrometry method. RESULTS: Minimal measurable blood levels were detectable at 7 days. Across all dose levels, individual T(max) values ranged from 1.00 hour and 12.00 hours; individual C(max) ranged from 0.73 ng/mL and 4.13 ng/mL. CONCLUSION: This study confirms the limited exposure of the systemic circulation of the eluted drug with the use of the Supralimus-Core® Sirolimus-Eluting Coronary Stent System (Sahajanand Medical Technologies Pvt. Ltd., Surat, India). In this study, sirolimus concentration in systemic circulation is to be safe, well-tolerated and short-lived.
OBJECTIVES: This study was conducted to assess the systemic drug release and distribution of sirolimus-eluting coronary stents. METHODS: Twenty patients with coronary artery disease (CAD) were treated with 1, 2, or 3 a newly designed metallic stents. Blood samples were drawn at 14 time points to determine the pharmacokinetic of sirolimus. Whole blood concentrations of sirolimus were determined by using a sensitive validated high-performance liquid chromatography mass spectrometry/mass spectrometry method. RESULTS: Minimal measurable blood levels were detectable at 7 days. Across all dose levels, individual T(max) values ranged from 1.00 hour and 12.00 hours; individual C(max) ranged from 0.73 ng/mL and 4.13 ng/mL. CONCLUSION: This study confirms the limited exposure of the systemic circulation of the eluted drug with the use of the Supralimus-Core® Sirolimus-Eluting Coronary Stent System (Sahajanand Medical Technologies Pvt. Ltd., Surat, India). In this study, sirolimus concentration in systemic circulation is to be safe, well-tolerated and short-lived.
Authors: T Suzuki; G Kopia; S Hayashi ; L R Bailey; G Llanos; R Wilensky; B D Klugherz; G Papandreou; P Narayan; M B Leon; A C Yeung; F Tio; P S Tsao; R Falotico; A J Carter Journal: Circulation Date: 2001-09-04 Impact factor: 29.690
Authors: Giora Weisz; Martin B Leon; David R Holmes; Dean J Kereiakes; Mel R Clark; Barry M Cohen; Stephen G Ellis; Patrick Coleman; Carolyn Hill; Chunxue Shi; Donald E Cutlip; Richard E Kuntz; Jeffrey W Moses Journal: J Am Coll Cardiol Date: 2006-03-20 Impact factor: 24.094
Authors: Bruce D Klugherz; Gerard Llanos; Warren Lieuallen; Gregory A Kopia; George Papandreou; Pallassana Narayan; Brett Sasseen; Steven J Adelman; Robert Falotico; Robert L Wilensky Journal: Coron Artery Dis Date: 2002-05 Impact factor: 1.439
Authors: David R Holmes; Martin B Leon; Jeffrey W Moses; Jeffrey J Popma; Donald Cutlip; Peter J Fitzgerald; Charles Brown; Tim Fischell; Shing Chiu Wong; Mark Midei; David Snead; Richard E Kuntz Journal: Circulation Date: 2004-02-10 Impact factor: 29.690
Authors: C R Gregory; X Huang; R E Pratt; V J Dzau; R Shorthouse; M E Billingham; R E Morris Journal: Transplantation Date: 1995-03-15 Impact factor: 4.939
Authors: Beatrice Semmling; Stefan Nagel; Katrin Sternberg; Werner Weitschies; Anne Seidlitz Journal: AAPS PharmSciTech Date: 2013-08-06 Impact factor: 3.246